Abandoning operations it purchased less than three years ago — and its ambitions of building a regenerative medicine powerhouse — Shire has sold its Dermagraft manufacturing plant in La Jolla.

NEW YORK (Reuters) - Shire Plc <SHP.L> sees a strong market for its recently acquired Dermagraft skin substitute due to surging rates of diabetes that can cause foot ulcers in a significant number of ...

DUBLIN, Ireland, January 17, 2014 – Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, today announced that it has entered into a definitive agreement pursuant to ...

Shire engendered some high expectations after the Irish biopharmaceutical giant acquired San Diego's Advanced BioHealing in 2011 for $750 million. Over the next year or so, Shire formed a new San ...

British speciality biopharmaceutical company Shire Plc today agreed to sell Dermagraft - a living skin substitute indicated for use in the treatment of full-thickness diabetic foot ulcers, to ...

EB refers to a group of rare genetic skin disorders which currently have no approved therapies as per Shire. The company intends to enrol approximately 20 patients (aged three years and above) ...

Advanced BioHealing, the San Diego maker of the Dermagraft skin patch, has been sold to Irish pharmaceutical company Shire for $750 million as executives quickly scuttled plans to take the business ...

LONDON—Shire PLC is getting out of its unsuccessful foray into the wound-care business by disposing of unprofitable skin product Dermagraft. The Dublin-based biopharmaceutical group will book a $650 ...